ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Sofosbuvir/Velpatasvir fixed dose combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study"
Episode Synopsis
Volume 4, Issue 8, Part 3.Raymond T. Chung, MD from Harvard Medical School interviews Dr. David Wyles from the University of California San Diego about his presentation: Sofosbuvir/Velpatasivr Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study, presented at the April 2016 EASL meeting.The post Sofosbuvir/Velpatasvir fixed dose combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.
More episodes of the podcast eViralHepatitis Review
Medications for CHB
20/10/2022
To Treat or Not To Treat
20/10/2022
HBV & Coinfections
20/10/2022
Hepatitis B: Our Current Understanding
20/10/2022
HBV: Next Steps to a Cure
03/08/2021
Treating HCV in PWID: Best Practices
10/04/2020
HCV: Management Beyond the Liver
04/03/2020
Avoiding “MELD Purgatory”
19/04/2019
Clinical Insight: Engaging PWID in HCV Care
28/12/2018
In God we trust